Comparing 1 month and 6 months of two blood-thinning medicines after leg artery procedures
Compares 1 month with 6 months of dual antiplatelet therapy in peripheral arterial disease.
Key facts
- Who runs it
- Corewell Health West
- Where
- Detroit and Grand Rapids, United StatesSee the 2 sites
- Trial code
- Registry title
- Vascular Trial Associated Registry Pilot
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 350 people, planned
- Started
- 15 Oct 2025
- Expected to end
- 30 Oct 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Clopidogrel (Plavix) Pharmacogenetic Test Reagents
- Record updated
- 16 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with narrowed leg arteries caused by plaque (atherosclerosis) who are having, or recently had, a procedure to open leg arteries from inside the vessel (PVI). It compares 1 month vs. 6 months of aspirin plus clopidogrel.
- Age
- 45 years or older
- Sex
- All sexes
- Disease stage
- Atherosclerotic vascular disease. The PVI must be scheduled or done in the last 30 days.
- Earlier treatment
- People on low dose rivaroxaban (2.5mg twice a day) with antiplatelet drugs can join only if they can stop these medicines.
Main reasons for not taking part
- Allergy to clopidogrel or aspirin, or unable to stop clopidogrel for other medical reasons
- High bleeding risk: past major bleeding, bleeding disorder, severe kidney problems (CrCl <30), platelet count <100,000, or blood thinners such as warfarin or full dose DOAC
- Stroke within the last 6 months
- Open bypass surgery at the same time as the procedure, or vessel disease not caused by plaque
- Pregnant women, prisoners, or people who cannot give consent themselves
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age greater than or equal to 45 at time of enrollment
- Patient is scheduled for a PVI or has recently had a PVI in the last 30 days
- Patient data is being submitted to Fivos, who is acting as the data collection subcontractor for the VQI-PVI registry
- Atherosclerotic vascular disease
Who cannot take part
- Patients on dual pathway inhibition (DPI) with low dose rivaroxaban (2.5mg twice a day) that are unable to stop these medications
- Allergy to Clopidogrel
- Allergy to aspirin
- Nonatherosclerotic vascular disease
- Patients with high bleeding risk (HBR) defined as:; History of major bleeding, active bleeding disorder, severe renal impairment (CrCl <30), concurrent anticoagulation, platelet count <100,000; Recent stroke (within 6 months); Current warfarin therapy or full dose therapeutic direct oral anticoagulants (DOAC)
- Patients who cannot consent for themselves
- Patients unable to stop clopidogrel for other medical reasons
- Patients undergoing open bypass at the same time as the peripheral transcutaneous angioplasty
- Patients unwilling or unable to comply with standard of care follow-up visits
- Pregnant women
- Prisoners
Where in United States
- Henry Ford HospitalDetroit, United StatesContact: Sarah MeehanTaking people
- Corewell Health WestGrand Rapids, United StatesContact: Stephen C Orey, MSTaking people
About the trial
What the trial wants to find out
The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.
The 2 groups in the trial
- Dual antiplatelet therapy 1-Month followed by single antiplatelet therapy indefinitelyExisting treatment, for comparison
Aspirin and Clopidogrel (Plavix) for 1-month post-procedure followed by Aspirin indefinitely. Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (Plavix) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).
Treatment: Clopidogrel (Plavix) Pharmacogenetic Test Reagents
- Dual antiplatelet therapy 6-Month followed by single antiplatelet therapy indefinitelyExisting treatment, for comparison
Aspirin and Clopidogrel (Plavix) for 6-months post-procedure followed by Aspirin indefinitely. Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (Plavix) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).
Treatment: Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Vascular Trial Associated Registry Pilot: Antiplatelet Therapies for Patients Undergoing Lower Extremity Endovascular Revascularization
- Plain-language title
- Comparing 1 month and 6 months of two blood-thinning medicines after leg artery proceduresGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 16 July 2026